CLL highlights from EHA and ICML: the CLL-12 study

Highlights from the EHA Conference - Chronic Lymphocytic Leukaemia (CLL)Подробнее

EHA 2023 CLL highlightsПодробнее

Highlights from ICML 2017: The CLL2-BAG studyПодробнее

CLL trial highlights from 15-ICMLПодробнее

Prof John Gribben: Highlights of CLL - ICML 2017Подробнее

Highlights of ICML 2021Подробнее

EHA 2020 CLL highlights: CLL14 & CAPTIVATEПодробнее

ICML 2017 HighlightsПодробнее

iCMLf Conversation: CML Highlights of EHA 2022 - Biological and clinical overviewПодробнее

Health-related quality of life with zanubrutinib versus ibrutinib for patients with R/R CLLПодробнее

Here's looking at you: CLL research to watchПодробнее

CLL highlights from ASH 2023: the FLAIR studyПодробнее

EPIC update: observational study of first-line acalabrutinib treatment for CLLПодробнее

Town Hall on ASCO, EHA & ICML - LymphomasПодробнее

iCMLf Conversation: CML Highlights of EHA 2023; Clinical and Biological OverviewПодробнее

Comment on fixed-duration venetoclax plus obinutuzumab in patients with CLL and comorbiditiesПодробнее

Updates in CLL from EHA 2024: combinations of BTK and BCL2 inhibitors, BTK degraders, and moreПодробнее

Highlights of ICML 2019Подробнее

Durable responses after CD19 CAR-T plus ibrutinib in CLLПодробнее